Back when we ran our "who's gonna get bought next" poll on the IN VIVO Blog most of you followed the herd--and chose Biogen Idec. All of you who chose "someone else," take a bow (we know you had Pharmion in mind). Tonight Celgene announced it was buying the cancer-focused biotech firm for $72 per share, for a grand total of $2.9 billion. We'll have more on this on Monday. (Had this deal not happened we may have gone with "While you weren't covering the spread against MIAMI.")
- In other news--does anyone else feel like the world is hurtling toward the 99-cent genome? Forget the $1000 genome, Bionanomatrix is touting its efforts toward a $100 genome (last Monday's Philly Inquirer). And on Friday consumer genomics hit the front pages, as Iceland's deCODE Gentics announced its deCODEme business and Google/Genentech-backed 23andme responded with a 'we're launching our business too' press release late Friday afternoon. Saturday's New York Times has a review of those efforts and more. The Financial Times chimes in as well.
- Barron's isn't confident that prasugrel's data is enough to buoy Lilly, reports Reuters.
- Just when you thought there was nothing more to write about insomnia. The New York Times magazine presents the 'sleep-industrial complex.'